Response to Comments: MolDX: EndoPredict Breast Cancer Gene Expression Test

This document is a response-to-comments notice regarding the MolDX EndoPredict Breast Cancer Gene Expression Test (LCD L37356) and contains only administrative information (comment and notice periods and effective date). It does not contain clinical coverage criteria, limitations, documentation requirements for claims, or frequency limits; consult the final LCD L37356 for actionable coverage rules.

"Document is a 'response to comments' notice for MolDX: EndoPredict (LCD L37356) and does not contain clinical coverage criteria; it records comment period (04/23/2020–07/07/2020), notice period sta..."

Sign up to see full coverage criteria, indications, and limitations.